Trials / Completed
CompletedNCT00614705
PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia
A Four Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2A Study Of PH-797804 In The Treatment Of Post-Herpetic Neuralgia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a proof-of-concept study to determine if PH-797804 reduces neuropathic pain associated with post-herpetic neuralgia. Suitable patients will be randomized to receive either PH-797804 or placebo for 4 weeks, during which time they will also record their pain symptoms using various pain scales.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PH-797804 | 6 mg dose in oral capsule form, once daily for 28 days |
| DRUG | Placebo | oral capsule form, once daily for 28 days |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2008-11-01
- Completion
- 2008-12-01
- First posted
- 2008-02-13
- Last updated
- 2011-05-16
Locations
25 sites across 6 countries: Chile, Russia, Spain, Sweden, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00614705. Inclusion in this directory is not an endorsement.